Welcome to our dedicated page for Xortx Therapeutics SEC filings (Ticker: XRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC filings from XORTX Therapeutics can read like a pharmacology textbook. Each 10-K packs dense clinical-trial tables, dilution clauses, and patent timelines that dictate the biotech’s outlook. For investors who type “XORTX Therapeutics SEC filings explained simply,” or need a quick answer on ADPKD trial enrollment, scrolling through 200 pages wastes valuable minutes.
Stock Titan’s platform delivers AI-powered summaries that turn complexity into clarity. The moment “XORTX Therapeutics insider trading Form 4 transactions” appear, we map them to price moves. A fresh “XORTX Therapeutics quarterly earnings report 10-Q filing” arrives with variance heat-maps and liquidity dashboards. Need “XORTX Therapeutics executive stock transactions Form 4,” “XORTX Therapeutics annual report 10-K simplified,” or to vet leadership pay when the “XORTX Therapeutics proxy statement executive compensation” lands? Our algorithms surface R&D spend, cash runway, and risk factors in plain English.
Because XORTX is pre-revenue, details buried in “XORTX Therapeutics 8-K material events explained” or a late-night S-1 can move the stock. Real-time alerts for “XORTX Therapeutics Form 4 insider transactions real-time” flag confidence shifts by leadership. Need deeper context? Our tools focus on patent life, licensing obligations, and clinical milestones—key metrics highlighted in every “XORTX Therapeutics earnings report filing analysis.” With expert commentary and instant EDGAR updates, understanding XORTX Therapeutics SEC documents with AI becomes a straightforward part of your research workflow.
XORTX Therapeutics Inc. filed a Form 6-K. The filing incorporates Exhibits 99.2 and 99.3 by reference into the company’s Registration Statement on Form F-3 (File No. 333-269429), adding legal opinions regarding the legality of securities being registered from Dentons Canada LLP and Troutman Pepper Locke LLP.
The exhibit index also lists a press release dated October 29, 2025 (Exhibit 99.1). The report is signed by President and Chief Executive Officer Allen Davidoff on October 31, 2025. This is an administrative update linking legal opinions to the existing F-3 shelf.
XORTX Therapeutics Inc. filed a Form 6-K furnishing transaction-related exhibits and incorporating them by reference into its Form F-3 registration statement (File No. 333-269429), as amended and supplemented.
The exhibits include a press release dated October 21, 2025, a Placement Agency Agreement with D. Boral Capital LLC, a form of Securities Purchase Agreement, a form of Lock-Up Agreement, and a form of Pre-Funded Common Share Purchase Warrant. The report was signed by President and CEO Allen Davidoff on October 22, 2025.
XORTX Therapeutics Inc. launched a registered direct offering to an institutional accredited investor, registering 572,470 common shares at $0.63 each, 1,177,530 pre-funded warrants at $0.62999 each with a $0.00001 exercise price, and 1,177,530 common shares underlying those warrants. The pre-funded warrants are immediately exercisable.
The fee table shows an aggregate offering price of $1,102,488, placement agent fees of $77,175, and proceeds before expenses of $1,025,313. The company estimates net proceeds of approximately $0.8 million for working capital and general corporate purposes. A beneficial ownership cap limits exercises above 4.99% (or, at the purchaser’s election at closing, 9.99%).
XRTX trades on the TSXV and Nasdaq. The company has applied to list the Shares and the Pre-Funded Warrant Shares on the TSXV and notified Nasdaq; TSXV approval is required. D. Boral Capital LLC is acting as exclusive placement agent on a best efforts basis. Delivery is expected on or about October 23, 2025, subject to customary conditions and TSXV approvals.
FAQ
What is the current stock price of Xortx Therapeutics (XRTX)?
What is the market cap of Xortx Therapeutics (XRTX)?
